Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04042103 · ClinicalTrials.gov registry record · Phase 2
Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis
A Phase 2 study of Plaque Psoriasis, sponsored by Organon and.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 6
- Study locations
NCT04042103: Completed Phase 2 study of Plaque Psoriasis, sponsored by Organon and.
NCT04042103 is a Phase 2 study of Plaque Psoriasis that has completed, run by Organon and. The registered enrollment target is 21 participants, below the 415-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (95% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04042103, a Phase 2 study of Plaque Psoriasis, has completed, sponsored by Organon and.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is an open-label, multicenter study to evaluate the systemic exposure and safety of topical tapinarof cream, 1% under conditions of maximal use in adults with plaque psoriasis.
Primary Outcome
Frequency and severity of AEs (local and systemic)
Conditions Studied
Interventions
- DRUG Tapinarof cream, 1%
Study Locations (6)
Texas
- Dermavant Investigational Site - Austin
- Dermavant Investigational Site - San Antonio
California
- Dermavant Investigational Site - Encino
Florida
- Dermavant Investigational Site - Sanford
Pennsylvania
- Dermavant Investigational Site - Philadelphia
Washington
- Dermavant Investigational Site - Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2019-07-23 |
| Est. Completion | 2020-01-09 |
| Phase | Phase 2 |
What the finished NCT04042103 record still lists
NCT04042103 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 415-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which Tapinarof cream, 1% is the first listed.
NCT04042103 lists 6 locations in 5 states (Texas, California, Florida).
Frequently Asked Questions
What is clinical trial NCT04042103 about?
NCT04042103 is a clinical study titled "Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis". This is an open-label, multicenter study to evaluate the systemic exposure and safety of topical tapinarof cream, 1% under conditions of maximal use in adults with plaque psoriasis.
What is the current status of trial NCT04042103?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2019-07-23. Estimated completion is 2020-01-09.
What conditions does trial NCT04042103 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT04042103?
The interventions under investigation include: Tapinarof cream, 1% (DRUG).
Who is sponsoring clinical trial NCT04042103?
This trial is sponsored by Organon and, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04042103 being conducted?
This trial has 6 study locations across California, Florida, Pennsylvania, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04042103's enrollment target sits among peer trials
21 45th of 45 higher than 1 of 45 other Plaque Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Plaque Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
RECRUITING · Phase 2
-
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
RECRUITING · Phase 2
-
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 2
-
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 2
-
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI